Alexander J. C. IJtsma
University Medical Center Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alexander J. C. IJtsma.
Medical Care Research and Review | 2009
Christian S. van der Hilst; Alexander J. C. IJtsma; Maarten J. H. Slooff; Elisabeth M. TenVergert
Large cost variations of liver transplantation are reported. The aim of this study was to assess cost differences of liver transplantation and clinical follow-up between the United States and other Organization for Economic Cooperation and Development (OECD) countries. Eight electronic databases were searched, and 2,000 citations published after 1990 with more than 10 transplantations, and with original cost data, were identified. A total of 30 articles included 5,975 liver transplantations. Meta-analysis was used to derive a combined mean using a random-effects model to test for heterogeneity between studies. Estimated mean cost of a U.S. liver transplantation was US
Liver Transplantation | 2009
Alexander J. C. IJtsma; Christian S. van der Hilst; Marieke T. de Boer; Koert P. de Jong; Paul M. J. G. Peeters; Robert J. Porte; Maarten J. H. Slooff
163,438 (US
Liver Transplantation | 2006
Danielle M. Nijkamp; Maarten J. H. Slooff; Christian S. van der Hilst; Alexander J. C. IJtsma; Koert P. de Jong; Paul M. J. G. Peeters; Robert J. Porte
145,277-181,598) compared to US
Transplant International | 2013
Christian S. van der Hilst; Alexander J. C. IJtsma; Jan T. Bottema; Bart van Hoek; Jeroen Dubbeld; Herold J. Metselaar; Geert Kazemier; Aad P. van den Berg; Robert J. Porte; Maarten J. H. Slooff
103,548 (US
Transplant International | 2016
Alexander J. C. IJtsma; Christian S. van der Hilst; Danielle M. Nijkamp; Jan T. Bottema; Vaclav Fidler; Robert J. Porte; Maarten J. H. Slooff
85,514-121,582) for other OECD countries. Patient characteristics, disease characteristics, quality of the health care provider, and methodology could not explain this cost difference. Health system characteristics differed between the U.S. and other OECD countries. Cost differences in liver transplantation between these two groups may be largely explained by health system characteristics.
Hepato-gastroenterology | 2006
Susumu Eguchi; Alexander J. C. IJtsma; Maarten J. H. Slooff; Robert J. Porte; Koert P. de Jong; Paul M. J. G. Peeters; Anette S. H. Gouw; Takashi Kanematsu
This study assesses the relation between the anhepatic phase duration and the outcome after liver transplantation. Of 645 patients who underwent transplantation between 1994 and 2006, 194 were recipients of consecutive adult primary piggyback liver transplants using heart‐beating donors. The anhepatic phase was defined as the time from the physical removal of the liver from the recipient to recirculation of the graft. Other noted study variables were the cold and warm ischemia times, donor and recipient age, donor and recipient body mass index, perioperative red blood cell (RBC) transfusion, indication for transplantation, and Model for End‐Stage Liver Disease score. The primary outcome parameter was graft dysfunction, which was defined as either primary nonfunction or initial poor function according to the Ploeg‐Maring criteria. The median anhepatic phase was 71 minutes (37–321 minutes). Graft dysfunction occurred in 27 patients (14%). Logistic regression analysis showed an anhepatic phase over 100 minutes [odds ratio (OR), 4.28], a recipient body mass index over 25 kg/m2 (OR, 3.21), and perioperative RBC transfusion (OR, 3.04) to be independently significant predictive factors for graft dysfunction. One‐year patient survival in patients with graft dysfunction was 67% versus 92% in patients without graft dysfunction (P < 0.001). A direct relation between the anhepatic phase duration and patient survival could, however, not be established. In conclusion, this study shows that liver transplant patients with an anhepatic phase over 100 minutes have a higher incidence of graft dysfunction. Patients with graft dysfunction have significantly worse 1‐year patient survival. Liver Transpl 15:1050–1055, 2009.
Journal of Gastrointestinal Surgery | 2008
Alexander J. C. IJtsma; Liselotte M. S. Boevé; Christian S. van der Hilst; Marieke T. de Boer; Koert P. de Jong; Paul M. J. G. Peeters; Annet S. H. Gouw; Robert J. Porte; Maarten J. H. Slooff
The exact frequency and clinical consequences of surgical hepatic injuries during organ procurement are unknown. We analyzed the incidence, risk factors, and clinical outcome of surgical injuries in 241 adult liver grafts. Hepatic injuries were categorized as parenchymal, vascular, or biliary. Outcome variables were bleeding complications, hepatic artery thrombosis (HAT), and graft survival. In 82 livers (34%), 96 injuries were detected. Most injuries were minor, but clinically relevant injuries were detected in 6.6% (16/241) of the livers. Fifty (21%) liver grafts had some degree of parenchymal or capsular injury, 40 (17%) had vascular injury, and 6 (2%) had an injury to the bile duct. Procurement region was the only risk factor significantly associated with surgical injury. The rate of hepatic artery injury was significantly higher in livers with aberrant arterial anatomy. Bleeding complications were found in 18% of patients who received livers with a parenchymal or capsular injury in contrast to 9% without parenchymal injury (P = 0.065). HAT was found in 23% of the patients who received a liver with arterial injury compared to 4% without arterial injury (P = 0.001). Overall graft survival rates were not significantly different for grafts with or without anatomical injury. In conclusion, surgical injuries of donor livers are an underestimated problem in liver transplantation and can be observed in about one‐third of all cases. Clinically relevant injuries are detected in 6.6% of all liver grafts. Arterial injuries are associated with an increased risk of HAT. Liver Transpl 12:1365‐1370, 2006.
Liver Transplantation | 2010
Alexander J. C. IJtsma; Christian S. van der Hilst; Danielle M. Nijkamp; Jan T. Bottema; Bart van Hoek; Geert Kazemier; Robert J. Porte; Maarten J. H. Slooff
This study aims to perform a detailed prospective observational multicenter cost‐effectiveness study by comparing liver transplantations with Donation after Brain Death (DBD) and Donation after Cardiac Death (DCD) grafts. All liver transplantations in the three Dutch liver transplant centers between 2004 and 2009 were included with 1‐year follow‐up. Primary outcome parameter was cost per life year after transplantation. Secondary outcome parameters were 1‐year patient and graft survival, complications, and patient‐level costs. From 382 recipients that underwent 423 liver transplantations, 293 were primarily transplanted with DBD and 89 with DCD organs. Baseline characteristics were not different between both groups. The Donor Risk Index was significantly different as were cold and warm ischemic time. Ward stay was significantly longer in DCD transplantations. Patient and graft survival were not significantly different. Patients receiving DCD organs had more and more severe complications. The cost per life year for DBD was € 88 913 compared to € 112 376 for DCD. This difference was statistically significant. DCD livers have more and more severe complications, more reinterventions and consequently higher costs than DBD livers. However, patient and graft survival was not different in this study. Reimbursement should be differentiated to better accommodate DCD transplantations.
Liver Transplantation | 2010
Michael E. Sutton; Jeroen Dubbeld; Alexander J. C. IJtsma; Geert Kazemier; Bart van Hoek; Herold J. Metselaar; Robert J. Porte
This study investigates the relationship between blood group and waiting time until transplantation or death on the waiting list. All patients listed for liver transplantation in the Netherlands between 15 December 2006 and 31 December 2012, were included. Study variables were gender, age, year of listing, diagnosis, previous transplantations, blood group, urgency, and MELD score. Using a competing risks analysis, separate cumulative incidence curves were constructed for death on the waiting list and transplantation and used to evaluate outcomes.In 517 listings, the mean death rate per 100 patient‐years was 10.4. A total of 375 (72.5% of all listings) were transplanted. Of all transplantations, 352 (93.9%) were ABO‐identical and 23 (6.1%) ABO‐compatible. The 5‐year cumulative incidence of death was 11.2% (SE 1.4%), and of transplantation 72.5% (SE 2.0%). Patient blood group had no multivariate significant impact on the hazard of dying on the waiting list nor on transplantation. Age, MELD score, and urgency status were significantly related to the death on the waiting list and transplantation. More recent listing had higher probability of being transplanted. In the MELD era, patient blood group status does not have a significant impact on liver transplant waiting list mortality nor on waiting time for transplantation.
Liver Transplantation | 2010
Michael E. Sutton; Jeroen Dubbeld; Alexander J. C. IJtsma; Geert Kazemier; Bart van Hoek; Herold J. Metselaar; Robert J. Porte